Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -67.22M | -49.02M | -33.82M | -32.09M | -31.74M |
Total Depreciation and Amortization | 76.00K | 48.00K | 36.00K | 29.00K | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 5.38M | 2.72M | 2.94M | 1.74M | -541.00K |
Change in Net Operating Assets | -5.96M | 3.73M | 1.54M | -1.31M | 2.52M |
Cash from Operations | -67.71M | -42.52M | -29.30M | -31.64M | -29.75M |
Capital Expenditure | 1.00K | -751.00K | -51.00K | -351.00K | -167.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 46.37M | -145.63M | -148.66M | -51.39M | -39.53M |
Cash from Investing | 46.37M | -146.38M | -148.71M | -51.74M | -39.69M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 44.36M | -- | 32.90M | 450.52M | -- |
Repurchase of Common Stock | -- | -32.66M | -- | -- | -213.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 33.05M | -33.05M | -- | -- |
Cash from Financing | 44.36M | 383.00K | -150.00K | 450.52M | -213.00K |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 23.01M | -188.52M | -178.16M | 367.14M | -69.66M |